Syngene Internation.
Ticker >

Syngene Internation. share price

Syngene International Ltd.

NSE: SYNGENE BSE: 539268 SECTOR: Business Support  125k   503   96

701.05
-4.20 (-0.60%)
NSE: 23 Apr 04:02 PM

Price Summary

Today's High

₹ 714.95

Today's Low

₹ 693.8

52 Week High

₹ 860.25

52 Week Low

₹ 619

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

₹ 28183.26 Cr.

Enterprise Value

₹ 28249.26 Cr.

No. of Shares

40.2 Cr.

P/E

60.52

P/B

7.16

Face Value

₹ 10

Div. Yield

0.18 %

Book Value (TTM)

₹  97.87

CASH

₹ 509.3 Cr.

DEBT

₹ 575.3 Cr.

Promoter Holding

54.79 %

EPS (TTM)

₹  11.58

Sales Growth

22.76%

ROE

13.99 %

ROCE

15.61%

Profit Growth

20.11 %

Add Your Ratio

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Index Presence

The company is present in 20 Indices.

NIFTYMIDCAP

NIFTY Midcap 100
49614.85
  518.449999999997 (1.05598373811522%)

NIFTY500

Nifty 500
20652.65
  77.8000000000029 (0.378131553814498%)

NIFTYMIDCAP150

Nifty Midcap 150
18417.95
  183.650000000001 (1.00716781011612%)

NIFTYMIDSMALL400

Nifty MidSmallcap 400
17411.85
  170.949999999997 (0.991537564744283%)

NY500MUL50:25:25

Nifty500 Multicap 50:25:25
14315.1
  82.8000000000011 (0.581775257688499%)

NIFTYLGEMID250

NIFTY LargeMidcap 250
14236.5
  83.3999999999996 (0.589270195222236%)

NIFTY200

Nifty 200
12478.35
  36.9500000000007 (0.296992299901944%)

NIFTYHEALTH

Nifty Healthcare Index
11639.35
  -111.65 (-0.950131903667772%)

NIFTYTOTALMCAP

Nifty Total Market index
11612.05
  45.9499999999989 (0.397281711207742%)

NIFTYFULLMIDCAP100

NIFTY FULL MIDCAP 100
5987.56
  -42.7999999999993 (-0.709742038617911%)

SMLCAP

S&P Bse Small Cap
46492.21
  484.010000000002 (1.0520081202916%)

BSE HC

S&P Bse Healthcare
34585.75
  -197.760000000002 (-0.568545267570764%)

BSE500

S&P Bse 500
32589.5
  99.619999999999 (0.306618553223337%)

MID150

S&P Bse 150 MidCap
13786.43
  89.6800000000003 (0.654753864967961%)

MSL400

S&P Bse 400 MidSmallCap
10570.7
  79.7000000000007 (0.759698789438579%)

BSE200

S&P Bse 200
10199.36
  20.0600000000013 (0.197066595934903%)

LMI250

S&P Bse 250 LargeMidCap
9669.36
  23.3000000000011 (0.241549399443919%)

ALLCAP

S&P Bse Allcap
9513.26
  33.7800000000007 (0.356348660475048%)

SMLSEL

S&P Bse SmallCap Select Index
6832.39
  70.2200000000003 (1.03842405618315%)

S&P MIDSMLCAP

S&P Bse MidSmallCap
11626.2
  92.0200000000004 (0.797802704656947%)

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.

PE Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

PB Chart 1w 1m 3m 6m 1Yr 3Yr 5Yr

* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year22.76%
3 Year16.65%
5 Year17.55%

Profit Growth

1 Year20.11%
3 Year4.75%
5 Year9.17%

ROE%

1 Year13.99%
3 Year14.6%
5 Year16.44%

ROCE %

1 Year15.61%
3 Year14.72%
5 Year16.13%

Debt/Equity

0.1618

Price to Cash Flow

33.62

Interest Cover Ratio

14.2942477876106

CFO/PAT (5 Yr. Avg.)

1.70209171759328

Share Holding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Mar 2024 54.79 0
Dec 2023 54.79 0
Sep 2023 54.79 0
Jun 2023 54.8 0
Mar 2023 54.88 0
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good revenue growth of 16.650384439721% for the Past 3 years.
  • Company has a healthy Interest coverage ratio of 14.2942477876106.
  • The Company has been maintaining an effective average operating margins of 29.3318085471248% in the last 5 years.
  • Company has a healthy liquidity position with current ratio of 2.0351680635963.
  • The company has a good cash flow management; CFO/PAT stands at 1.70209171759328.
  • The company has a high promoter holding of 54.79%.

 Limitations

  • The company has shown a poor profit growth of 4.75234816978987% for the Past 3 years.
  • Company has contingent liabilities of 1243.8 Cr.
  • The company is trading at a high PE of 60.52.

Quarterly Result (All Figures in Cr.)

PARTICULARS Dec 2022 Mar 2023 Jun 2023 Sep 2023 Dec 2023
Net Sales 786.6 994.4 715.8 830.7 791.9
Total Expenditure 556.2 678 552.4 614.1 592.4
Operating Profit 230.4 316.4 163.4 216.6 199.5
Other Income 17.2 22.8 22.9 21 28.8
Interest 13.7 10.4 6.1 8.6 6.3
Depreciation 94.6 88.1 88.7 90.9 93.6
Exceptional Items 0 0 0 -7.4 -3.7
Profit Before Tax 139.3 240.7 91.5 130.7 124.7
Tax 29.8 51.7 16.2 29.1 24.9
Profit After Tax 109.5 189 75.3 101.6 99.8
Adjusted EPS (Rs) 2.73 4.71 1.87 2.53 2.48

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Net Sales 1825.6 2011.9 2179.4 2601.4 3193.5
Total Expenditure 1291.1 1409.7 1528.1 1863.6 2260.9
Operating Profit 534.5 602.2 651.3 737.8 932.6
Other Income 76.2 96.1 83.3 108.4 72.6
Interest 32.3 34.6 27.7 24.1 45.2
Depreciation 164.2 219.3 274.5 309.7 359.1
Exceptional Items 0 71.3 35 -30.7 0
Profit Before Tax 414.2 515.7 467.4 481.7 600.9
Tax 83.5 104.2 63.7 87.9 127.9
Net Profit 330.7 411.5 403.7 393.8 473
Adjusted EPS (Rs.) 8.27 10.29 10.09 9.83 11.78

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Equity and Liabilities
Share Capital 200 400 400 400.8 401.4
Total Reserves 1767.2 1774.1 2418.3 2891.2 3217.5
Borrowings 346.6 0 512.4 531.5 489
Other N/C liabilities 168.4 325.2 327.7 440.7 291.4
Current liabilities 1128.6 1540 1130.4 1231.5 1157.3
Total Liabilities 3610.8 4039.3 4788.8 5495.7 5768.5
Assets
Net Block 1336.8 1983.7 2163.4 2354.3 2211.9
Capital WIP 273.7 234.1 237.2 346.4 126.2
Intangible WIP 0 0 0 0 0
Investments 0.3 38.3 279 270.6 116.4
Loans & Advances 121.9 107.8 115.1 150.7 164.5
Other N/C Assets 115.5 64 193.1 170.1 794.2
Current Assets 1762.6 1611.4 1801 2203.6 2355.3
Total Assets 3610.8 4039.3 4788.8 5495.7 5768.5
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2019 Mar 2020 Mar 2021 Mar 2022 Mar 2023
Profit from operations 414.2 515.7 467.4 481.7 600.9
Adjustment 129 223.2 278.6 381.3 375.3
Changes in Assets & Liabilities 182.3 44.9 34.8 -176.6 -4.1
Tax Paid -95.7 -106.4 -82.8 -104.2 -133.7
Operating Cash Flow 629.8 677.4 698 582.2 838.4
Investing Cash Flow -645.5 -423.8 -628.9 -610.8 -685.1
Financing Cash Flow -72.4 -225.5 58 -31.3 -340.2
Net Cash Flow -88.1 28.1 127.1 -59.9 -186.9

Corporate Actions

Investors Details

PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
promoters 54.88 54.80 54.79 54.79 54.79
biocon limited 54.60 54.52 54.52 54.52 54.52
biocon limited employee w... - 0.27 0.26 0.26 0.26
kiran mazumdar shaw 0.01 0.01 0.01 0.01 0.01
biocon limited employee w... 0.27 - - - -
PARTICULARS Mar 2023% Jun 2023% Sep 2023% Dec 2023% Mar 2024%
investors 45.12 45.20 45.21 45.21 45.21
government of singapore 3.93 3.71 2.94 2.94 2.94
government pension fund g... 1.84 1.75 2.10 2.19 2.22
icici prudential business... - - - - 5.97
kotak funds - india midca... - - 1.27 1.27 1.23
life insurance corporatio... - - - - 1.18
mirae asset healthcare fu... - 1.06 1.04 - 1.21
uti-mid cap fund - - - - 1.81
icici prudential pharma h... 2.18 - - 5.06 -
mirae asset nifty midcap ... - - - 1.16 -
uti-unit linked insurance... 1.39 - 1.46 1.46 -
icici prudential midcap f... - - 2.13 - -
invesco india arbitrage f... 1.14 - 1.10 - -
icici prudential midcap 1... - 1.87 - - -
independent directors - 0.02 - - -
invesco india flexi cap f... - 1.18 - - -
uti nifty 200 momentum 30... - 1.49 - - -
mirae asset focused fund 1.25 - - - -

Annual Reports

Ratings & Research Reports

Company Presentations

Company News

Syngene International informs about disclosure30 Mar 2024, 11:13AM Syngene International informs about analyst meet 21 Feb 2024, 5:10PM Syngene Internation. - Quaterly Results25 Jan 2024, 2:31PM Syngene Internation. - Quaterly Results25 Jan 2024, 2:31PM Syngene Internation. - Quaterly Results25 Jan 2024, 2:31PM Syngene International informs about update23 Dec 2023, 11:53AM Syngene International informs about analyst meet14 Dec 2023, 5:21PM Syngene International submits intimation on analyst meeting11 Dec 2023, 5:17PM Syngene International informs about analyst meet 6 Dec 2023, 5:03PM Syngene International concludes acquisition of biologics manufacturing facility2 Dec 2023, 4:08PM Syngene International reports 14% rise in Q2 consolidated net profit18 Oct 2023, 11:50AM Syngene Internation. - Quaterly Results17 Oct 2023, 6:43PM Syngene Internation. - Quaterly Results17 Oct 2023, 6:43PM Syngene Internation. - Quaterly Results17 Oct 2023, 6:43PM Syngene International submits analyst meet intimation21 Aug 2023, 5:02PM Syngene International informs about voting results and scrutinizer’s report28 Jul 2023, 9:58AM Syngene Internation. - Quaterly Results26 Jul 2023, 3:26PM Syngene Internation. - Quaterly Results26 Jul 2023, 3:26PM Syngene Internation. - Quaterly Results26 Jul 2023, 3:26PM Syngene International to acquire Unit 3 biologics manufacturing facility from Stelis Biopharma 5 Jul 2023, 9:26AM Syngene International submits analyst meet intimation19 Jun 2023, 5:00PM Syngene International informs about analyst meet6 Jun 2023, 4:17PM Syngene International submits analyst meet intimation2 Jun 2023, 4:57PM Syngene International submits analyst meet intimation24 May 2023, 5:13PM Syngene International informs about analyst meet16 May 2023, 1:38PM Syngene International reports 21% rise in Q4 consolidated net profit27 Apr 2023, 1:01PM Syngene Internation. - Quaterly Results26 Apr 2023, 6:54PM Syngene Internation. - Quaterly Results26 Apr 2023, 6:54PM Syngene Internation. - Quaterly Results26 Apr 2023, 6:54PM Syngene International informs about board meeting 8 Apr 2023, 12:21PM Syngene International informs about newspaper publication 25 Mar 2023, 2:43PM Syngene International submits analyst meet intimation3 Mar 2023, 5:08PM Syngene International submits analyst meet intimation27 Feb 2023, 4:51PM Syngene International informs about analyst meet 21 Feb 2023, 3:24PM Syngene International informs about analyst meet 20 Feb 2023, 12:41PM Syngene International informs about cancellation of conference call17 Feb 2023, 9:56AM Syngene International informs about investors meet30 Jan 2023, 12:18PM Syngene International informs about analyst meet 27 Jan 2023, 12:42PM Syngene Internation. - Quaterly Results23 Jan 2023, 8:02PM Syngene Internation. - Quaterly Results23 Jan 2023, 8:02PM Syngene International informs about cancellation of investor meeting 28 Dec 2022, 10:55AM Syngene International informs about analyst meet 19 Dec 2022, 12:31PM Syngene International informs about analyst meet 19 Dec 2022, 12:25PM Syngene International informs about analyst meet12 Dec 2022, 12:02PM USFDA conducts inspection at Syngene International’s Biologics facility15 Nov 2022, 5:53PM Syngene International informs about updates15 Nov 2022, 5:22PM Syngene International informs about investor presentation19 Oct 2022, 5:01PM Syngene International informs about outcome of board meeting 19 Oct 2022, 4:36PM Syngene International informs about press release19 Oct 2022, 3:43PM Syngene International informs about outcome of board meeting19 Oct 2022, 3:17PM

Syngene Internation. Stock Price Analysis and Quick Research Report. Is Syngene Internation. an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Syngene Internation. . 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Syngene Internation. has a PE ratio of 60.5182966307266 which is high and comparatively overvalued .

  • Share Price: - The current share price of Syngene Internation. is Rs 701.05. One can use valuation calculators of ticker to know if Syngene Internation. share price is undervalued or overvalued.

  • Return on Assets (ROA): - Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Syngene Internation. has ROA of 8.39828838266366 % which is a bad sign for future performance. (higher values are always desirable)

  • Current ratio: - The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Syngene Internation. has a Current ratio of 2.0351680635963 .

  • Return on equity: - ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Syngene Internation. has a ROE of 13.9918060670601 % .(higher is better)

  • Debt to equity ratio: - It is a good metric to check out the capital structure along with its performance. Syngene Internation. has a Debt to Equity ratio of 0.1618 which means that the company has low proportion of debt in its capital.

  • Sales growth: - Syngene Internation. has reported revenue growth of 22.7608210963328 % which is fair in relation to its growth and performance. 

  • Operating Margin: - This will tell you about the operational efficiency of the company. The operating margin of Syngene Internation. for the current financial year is 29.2030687333646 %.

  • Dividend Yield: - It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Syngene Internation. is Rs 1.25 and the yield is 0.1781 %.

  • Earnings Per Share: - It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Syngene Internation. is Rs 11.5841 . The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Syngene Internation. in Ticker for free. Also, one can get the intrinsic value of Syngene Internation. by using Valuation Calculators, which are available with a Finology ONE subscription. 

Last Updated on:
Brief about Syngene Internation.

Syngene International Ltd. Financials: Check Share Price, Balance Sheet, Annual Report and Quarterly Results for Company Analysis

 

Syngene International Ltd. is a leading contract research organization (CRO) in India, providing integrated drug discovery and development services to the global pharmaceutical industry.  We will provide a comprehensive analysis of Syngene International Ltd.'s stock performance and key financial indicators.

Syngene International Ltd. Share Price

Syngene International Ltd.'s share price has been consistently increasing over the years due to the company's strong financial performance and growth prospects. The company has a stable business model and a diverse range of clients, which provides investors with a sense of security and stability. Investors can use our pre-built screening tools to track Syngene International Ltd.'s share price and compare it with other companies in the industry.

Syngene International Ltd. Balance Sheet

Syngene International Ltd.'s balance sheet is a reflection of the company's financial health and stability. The company has a strong balance sheet with a healthy debt-to-equity ratio and a high current ratio. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Syngene International Ltd. Annual Report

Syngene International Ltd.'s annual reports provide detailed information about the company's operations, financial performance, and future prospects. Investors can download the annual reports from Ticker and analyze the company's performance over the years. The annual report also includes information about the company's management team, corporate governance practices, and sustainability initiatives.

Syngene International Ltd. Dividend

Syngene International Ltd. has a consistent track record of paying dividends to its shareholders. The company has a dividend payout ratio of over 50%, which indicates that it is committed to sharing its profits with its shareholders. Investors can track Syngene International Ltd.'s dividend history using our pre-built screening tools and compare it with other companies in the industry.

Syngene International Ltd. Quarterly Result

Syngene International Ltd.'s quarterly results provide an insight into the company's performance over a shorter period. The company's revenue and profits can be affected by various factors such as changes in government policies, fluctuations in commodity prices, and global economic conditions. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis. These tools provide investors with a comprehensive understanding of the company's financial position and help them make informed investment decisions.

Syngene International Ltd. Stock Price

Syngene International Ltd.'s stock price is influenced by various factors such as the company's financial performance, market conditions, and investor sentiment. Investors can track Syngene International Ltd.'s stock price using our pre-built screening tools and compare it with other companies in the industry. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Syngene International Ltd. Price Chart

Syngene International Ltd.'s price chart provides a visual representation of the company's stock performance over a period of time. Investors can use our pre-built screening tools to analyze Syngene International Ltd.'s price chart and compare it with other companies in the industry. Our premium features allow fair value calculation using tools such as DCF Analysis, BVPS Analysis, Earnings multiple approach, and DuPont analysis.

Syngene International Ltd. News

Syngene International Ltd.'s news section provides investors with the latest updates about the company's operations, financial performance, and future prospects. Investors can stay informed about the company's developments by regularly checking the news section on Ticker.

Syngene International Ltd. Concall Transcripts

Syngene International Ltd.'s concall transcripts provide investors with an opportunity to listen to the management team's views on the company's performance and future prospects. Investors can download the concall transcripts from Ticker and gain valuable insights into the company's operations.

Syngene International Ltd. Investor Presentations

Syngene International Ltd.'s investor presentations provide a comprehensive overview of the company's operations, financial performance, and future prospects. Investors can download the investor presentations from Ticker and gain a deeper understanding of the company's business model and growth prospects.

Syngene International Ltd. Promoters

Syngene International Ltd.'s promoters include Biocon, a leading biotechnology company in India. The company has a strong backing from its promoters, which provides investors with a sense of security and stability.

Syngene International Ltd. Shareholders

Syngene International Ltd.'s shareholders include retail investors, institutional investors, and the company's promoters. The company has a diverse shareholder base, which indicates that it is a popular investment choice among investors.

Read More
X